ProQR Therapeutics NV (PRQR.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|31||2012||Founding Chief Executive Officer|
|50||Co-Founder, Chief Innovation Officer|
|2014||Chief Financial Officer|
|50||Chief Corporate Development Officer and General Counsel|
|2017||Chief Development Strategy Officer|
- BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa
- BRIEF-Proqr reports loss of EUR 0.42 per share
- BRIEF-ProQR Therapeutics prices public offering
- BRIEF-Proqr announces proposed public offering of ordinary shares
- BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110